Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
Efficacy of Modified Release Metaxalone 640 mg in Acute Lumbosacral Musculoskeletal Conditions With Spinal Stenosis and Sciatica
Primus Pharmaceuticals
50 participants
Nov 15, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about: * Amount and quality of pain * Interference with physical activity * Interference with sleep
Eligibility
Inclusion Criteria4
- No clinically significant conditions impacting quality or quantity of pain
- Baseline Numeric Pain Scale ≥ 6
- Capable of answering text or email survey reminders
- Low back pain with or without sciatica
Exclusion Criteria3
- Current use of other skeletal relaxants
- Current use of other pain relievers
- Current use of cimetidine or monoamine oxidase inhibitors
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.
Locations(24)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06157177